Home›The Library›Taspoglutide
Taspoglutide
Taspoglutide is a real once-weekly GLP-1 analog that went through an eight-trial, 6,000-plus-patient Phase 3 program with genuinely strong glycemic results — and was never approved anywhere. Roche halted all dosing in September 2010 after a serious hypersensitivity signal, including anaphylaxis, combined with unacceptably high discontinuation rates from GI side effects, and permanently ended development soon after.
On this page
In brief
Should you care? This drug never reached market and isn't a live grey-market product — it's here as a case study in a GLP-1 candidate that worked in its trials and still didn't survive them, a useful third data point alongside this site's albiglutide (business-driven withdrawal) and peginesatide (post-approval safety withdrawal) pages.The short version
- A GLP-1 analog altered by just two amino acids (Aib substitutions at positions 8 and 35 of native human GLP-1), discovered by Ipsen and licensed to Roche in 2006 for once-weekly subcutaneous dosing.
- Real Phase 3 efficacy: the T-emerge program (eight trials, 6,000+ patients) found HbA1c reductions of roughly 1.0-1.3 percentage points and outperformed twice-daily exenatide on glycemic control.
- Halted in September 2010 after Roche found unacceptably high discontinuation rates from GI side effects and a serious hypersensitivity/anaphylaxis signal — development was never resumed, and no country ever approved it.
A minimally-modified analog of native human GLP-1
Taspoglutide (originally BIM-51077) was discovered by Ipsen and licensed to Roche in 2006 for worldwide development and marketing outside Japan, where Ipsen separately licensed it to Teijin. Where exenatide is derived from Gila monster venom and liraglutide and semaglutide carry a fatty-acid side chain for albumin binding, taspoglutide took a more conservative approach: two amino-acid substitutions (Aib at positions 8 and 35) on the native human GLP-1(7-36) sequence, just enough to resist the DPP-4 enzyme that normally clears GLP-1 from circulation within minutes (Dong et al., Diabetes Obes Metab 2011;13(1):19-25, PMID 21114599). Formulated for once-weekly subcutaneous injection, it entered Roche's "T-emerge" Phase 3 program for type 2 diabetes starting around 2008.
The T-emerge Phase 3 program's real efficacy data
T-emerge 1, a 24-week, randomized, double-blind, placebo-controlled trial in 373 drug-naive type 2 diabetes patients, found HbA1c fell 1.01 percentage points on 10mg and 1.18 points on 20mg weekly taspoglutide, versus 0.09 points on placebo (Raz I, Fonseca V, Kipnes M, et al., Diabetes Care 2012;35(3):485-487, PMID 22301126). T-emerge 2, a head-to-head, open-label trial against twice-daily exenatide in 1,189 patients on background metformin (± a thiazolidinedione), found both taspoglutide doses reduced HbA1c significantly more than exenatide (10mg: -1.24%; 20mg: -1.31%; exenatide: -0.98%), with comparable weight loss (Rosenstock J, Balas B, Charbonnel B, et al., Diabetes Care 2013;36(3):498-504, PMID 23139373, DOI 10.2337/dc12-0709). This was a real, adequately-powered efficacy program — the drug did not fail because it didn't work.
The hypersensitivity signal that ended it
A safety halt, not a business decision
In September 2010, Roche voluntarily stopped all further dosing across the entire T-emerge Phase 3 program — not one trial, all of them — citing higher-than-expected discontinuation rates driven mainly by GI intolerability (nausea reported in up to 59% and vomiting in up to 37% of taspoglutide patients in T-emerge 2 alone) together with a risk-mitigation plan triggered by serious hypersensitivity reactions, including anaphylactic and anaphylactoid events, occurring in under 1% of patients but at a rate the companies judged unacceptable for this drug class.
After further root-cause and reformulation work with Ipsen failed to resolve the hypersensitivity profile, Roche discontinued development entirely and returned full rights to Ipsen. No marketing application was ever filed with the FDA, EMA, or any other regulator before the program was stopped, and no company has advanced the molecule since.
Why this case study matters
This site already covers two other discontinued injectable hormone drugs from a similar era: albiglutide, pulled for purely commercial reasons after later proving itself in a positive cardiovascular-outcomes trial, and peginesatide, withdrawn after real-world fatal reactions surfaced after approval. Taspoglutide is the missing third case: a drug with real, adequately-powered efficacy data that never got the chance to reach a pharmacy shelf at all, because its safety signal showed up during the trials themselves rather than after launch. "Worked in the trials" and "safe enough to approve" are two different bars, and a real drug can clear the first without ever clearing the second.
References
- Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R, "Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (T-emerge 1)," Diabetes Care 2012;35(3):485-487, PMID 22301126.
- Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R, "The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 Trial," Diabetes Care 2013;36(3):498-504, PMID 23139373, DOI: 10.2337/dc12-0709.
- Dong JZ, Shen Y, Zhang J, Tsomaia N, Mierke DF, Taylor JE, "Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes," Diabetes Obes Metab 2011;13(1):19-25, PMID 21114599.
- Contemporary trade-press coverage of Roche's September 2010 suspension of T-emerge dosing and the subsequent decision to discontinue development and return rights to Ipsen, cross-checked against the T-emerge 2 trial's own published safety narrative for the underlying adverse-event figures.